The company was established in Asia in China. The main office of represented VC is situated in the Shenzhen.
The current fund was established by Weichun Jin.
The fund is generally included in less than 2 deals every year. The usual things for fund are deals in the range of 1 - 5 millions dollars. The high activity for fund was in 2018.
The usual cause for the fund is to invest in rounds with 1 partaker.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. We can highlight the next thriving fund investment areas, such as Medical Device, Health Care. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Kangso Medical Inspection.
Related Funds
Funds with similar focus
Fund Name | Location |
Blue Slide Ventures | New York, New York, United States |
BrilliMedical International Corporation | - |
Cox Orange Investment Ltd | Canada, Lions Head, Ontario |
Faering Capital | India, Maharashtra, Mumbai |
Flashstarts | Cleveland, Ohio, United States |
GiDi Venture Capital | Lagos, Lagos, Nigeria |
Innalabs Holding | Dulles, United States, Virginia |
Innovation Fund Macedonia | - |
International Securities Exchange Holdings | New York, New York, United States |
Meaningful Partners | California, El Segundo, United States |
Monex Precious Metals | California, Newport Beach, United States |
NewBornTown | Beijing, Beijing, China |
Omicron Media | Florida, United States, Winter Park |
Patria Mobile | - |
Powershift Group | Austin, Texas, United States |
Sa Sa International Holdings | - |
Sinvo Group | Beijing, China, Haidian |
United Capital | China, Fujian, Hunan |
ZCash Foundation | - |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Guyan New Materials | 04 Jul 2024 | Shenzhen, Guangdong, China | |||
Kunhua Technology | $15M | 03 Jul 2023 | Jiading, Shanghai, China | ||
Furong Biotech | $15M | 06 Feb 2023 | Suzhou, Jiangsu, China | ||
Zezheng Pharmaceutical | $15M | 27 Dec 2021 | Jiading, Shanghai, China | ||
Huaxian Pharmaceutical | $23M | 01 Sep 2021 | Guangdong, Tianjin, China | ||
Cospowers | 01 Oct 2020 | Dongying, Shandong, China | |||
Thoth Medical | 01 Jan 2020 | Suzhou, Jiangsu, China | |||
Kangso Medical Inspection | $2M | 20 Aug 2018 | China, Beijing | ||
ACCB Biotech | 01 Apr 2017 | Dongcheng District, Beijing, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Guyan New Materials | 04 Jul 2024 | Shenzhen, Guangdong, China | |||
Kunhua Technology | $15M | 03 Jul 2023 | Jiading, Shanghai, China | ||
Furong Biotech | $15M | 06 Feb 2023 | Suzhou, Jiangsu, China | ||
Zezheng Pharmaceutical | $15M | 27 Dec 2021 | Jiading, Shanghai, China | ||
Huaxian Pharmaceutical | $23M | 01 Sep 2021 | Guangdong, Tianjin, China | ||
Cospowers | 01 Oct 2020 | Dongying, Shandong, China | |||
Thoth Medical | 01 Jan 2020 | Suzhou, Jiangsu, China | |||
Kangso Medical Inspection | $2M | 20 Aug 2018 | China, Beijing | ||
ACCB Biotech | 01 Apr 2017 | Dongcheng District, Beijing, China |